Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan

Journal of Diabetes and its Complications

Volumn 29, Issue 8, 2015, Pages 1304-1309

  Seino, Yutaka ^a   Yabe, Daisuke ^a   Takami, Akane ^b   Niemoeller, Elisabeth ^c   Takagi, Hiroki ^b  

^a KANSAI ELECTRIC POWER CO   (Japan)

^b Sanofi ^*  (Japan)

^c Sanofi   (Germany)

Author keywords

FPG; GLP 1; HbA1c; Safety; TEAE; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LIXISENATIDE; ANTIDIABETIC AGENT; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PEPTIDE; ZP10A PEPTIDE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DIARRHEA; DRUG DOSE INCREASE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROENTERITIS; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; JAPANESE (PEOPLE); LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING; WEIGHT REDUCTION; AGONISTS; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; HYPERGLYCEMIA; INCIDENCE; INTENTION TO TREAT ANALYSIS; JAPAN; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT DROPOUT; PHASE 3 CLINICAL TRIAL; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; INJECTIONS, SUBCUTANEOUS; INTENTION TO TREAT ANALYSIS; JAPAN; MALE; MIDDLE AGED; NAUSEA; PATIENT DROPOUTS; PEPTIDES; SEVERITY OF ILLNESS INDEX; WEIGHT LOSS;

EID: 84948716781     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2015.07.003     Document Type: Article

References (35)

1. B. Ahren, A. Leguizamo Dimas, P. Miossec, S. Saubadu, and R. Aronson Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M) Diabetes Care 36 2013 2543 2550
2. J.B. Buse, M. Nauck, T. Forst, W.H. Sheu, S.K. Shenouda, C.R. Heilmann, and et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study Lancet 381 2013 117 124
3. D.J. Drucker, J.B. Buse, K. Taylor, D.M. Kendall, M. Trautmann, D. Zhuang, and et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study Lancet 372 2008 1240 1250
4. D.J. Drucker, and M.A. Nauck The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 2006 1696 1705
5. V.A. Fonseca, R. Alvarado-Ruiz, D. Raccah, G. Boka, P. Miossec, J.E. Gerich, and et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono) Diabetes Care 35 2012 1225 1231
6. M. Horowitz, C.K. Rayner, and K.L. Jones Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes Advances in Therapy 30 2013 81 101
7. N. Inagaki, Y. Atsumi, T. Oura, H. Saito, and T. Imaoka Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): Results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study Clinical Therapeutics 34 2012 1892 1908
8. N. Inagaki, K. Ueki, A. Yamamura, H. Saito, and T. Imaoka Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes Journal of Diabetes Investigation 2 2011 448 456
9. International Diabetes Federation IDF diabetes atlas 5th edition Update, country estimates table 2012 http://www.idf.org/diabetesatlas/5e/Update2012 2013
10. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck, and et al. Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 55 2012 1577 1596
11. T. Kadowaki, M. Namba, T. Imaoka, A. Yamamura, W. Goto, M.K. Boardman, and et al. Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks Journal of Diabetes Investigation 2 2011 210 217
12. K. Kaku, M.F. Rasmussen, M. Nishida, and Y. Seino Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes Journal of Diabetes Investigation 2 2011 441 447
13. A. Kashiwagi, M. Kasuga, E. Araki, Y. Oka, T. Hanafusa, H. Ito, and et al. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values Journal of Diabetes Investigation 3 2012 39 40
14. R. Kawamori Diabetes trends in Japan Diabetes/Metabolism Research and Reviews 18 Suppl. 3 2002 S9 S13
15. 1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: A systematic review and meta-analysis Diabetes, Obesity & Metabolism 16 2014 900 909
16. M. Lorenz, C. Pfeiffer, A. Steinsträsser, R.H. Becker, H. Rütten, P. Ruus, and et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes - relationship to postprandial glycemia Regulatory Peptides 185 2013 1 8
17. J.J. Meier GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus Nature Reviews Endocrinology 8 2012 728 742
18. M. Namba, T. Katsuno, Y. Kusunoki, T. Matsuo, M. Miuchi, J. Miyagawa, and et al. New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy Clinical and Experimental Nephrology 17 2013 10 15
19. Y. Onishi, H. Koshiyama, T. Imaoka, H. Haber, J. Scism-Bacon, M.K. Boardman, and et al. Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus Journal of Diabetes Investigation 4 2012 182 189
20. M. Pinget, R. Goldenberg, E. Niemoeller, I. Muehlen-Bartmer, H. Guo, and R. Aronson Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P) Diabetes, Obesity & Metabolism 15 2013 1000 1007
21. M.C. Riddle, R. Aronson, P. Home, M. Marre, E. Niemoeller, P. Miossec, and et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L) Diabetes Care 36 2013 2489 2496
22. M.C. Riddle, T. Forst, R. Aronson, L. Sauque-Reyna, E. Souhami, L. Silvestre, and et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1) Diabetes Care 36 2013 2497 2503
23. J. Rosenstock, D. Raccah, L. Koranyi, L. Maffei, G. Boka, P. Miossec, and et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X) Diabetes Care 36 2013 2945 2951
24. ® is first diabetes therapy of its class approved in Japan for use in combination with basal insulin http://en.sanofi.com/Images/33261-20130628-LYXUMIA-en.pdf 2013
25. Y. Seino, M. Fukushima, and D. Yabe GIP and GLP-1, the two incretin hormones: Similarities and differences Journal of Diabetes Investigation 1 2010 8 23
26. Y. Seino, K.W. Min, E. Niemoeller, A. Takami, and Investigators EG-LAS Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia) Diabetes, Obesity & Metabolism 14 2012 910 917
27. Y. Seino, M.F. Rasmussen, P. Clauson, and K. Kaku The once-daily human glucagon-like peptide-1 analog, liraglutide, improves β-cell function in Japanese patients with type 2 diabetes Journal of Diabetes Investigation 3 2012 388 395
28. Y. Seino, M.F. Rasmussen, T. Nishida, and K. Kaku Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes Current Medical Research and Opinion 26 2010 1013 1022
29. Y. Seino, M.F. Rasmussen, M. Nishida, and K. Kaku Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial Journal of Diabetes Investigation 2 2011 280 286
30. Y. Seino, and D. Yabe Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas Journal of Diabetes Investigation 4 2013 108 130
31. S.-J. Shin Glucagon-like peptide-1 receptor agonists and their effects on weight reduction Journal of Diabetes Investigation 3 2012 490 491
32. S. van Dieren, S. Czernichow, J. Chalmers, A.P. Kengne, B.E. de Galan, N. Poulter, and et al. Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial Diabetes, Obesity & Metabolism 14 2012 464 469
33. D. Yabe, A. Kuroe, S. Lee, K. Watanabe, T. Hyo, M. Hishizawa, and et al. Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls Journal of Diabetes Investigation 1 2010 56 59
34. D. Yabe, and Y. Seino Two incretin hormones GLP-1 and GIP: Comparison of their actions in insulin secretion and beta cell preservation Progress in Biophysics and Molecular Biology 107 2011 248 256
35. D. Yabe, K. Watanabe, K. Sugawara, H. Kuwata, Y. Kitamoto, K. Sugizaki, and et al. Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes Journal of Diabetes Investigation 3 2012 70 79